Immunotherapeutic Approaches of Rheumatic Disorders

References

• Arend WP. The pathophysiology and treatment of rheu-matoid arthritis. Arthritis Rheum. 1997; 40: 595–97.
   Google Scholar
• Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988; 2: 706–9.
   Google Scholar
• Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1125–32.
   Google Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumor ne-crosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sei USA. 1992; 89. 9784–88.
   Google Scholar
• Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established Type II collagen-induced arthritis in DBA/mice. A comparative study using anti-TNF-α, anti-IL-lα/β, and IL- lRa. Arthritis Rheum. 1996; 39: 797–809.
   Google Scholar
• Keffer J, Probert L, Caziaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic modei of arthritis. EM BO J. 1991; 10: 4025 31.
   Google Scholar
• Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 151–60.
   Google Scholar
• Moreland LW, Heck LW Jr, Koopamn WL Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997; 40: 397–409.
   Google Scholar
• Weckmann AL, Alcocer-Varela J. Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum. 1996; 26: 539–57.
   Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FN, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum. 1993; 36: 1681–90.
   Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344 : 1105–1110.
   Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bifl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994; 344: 1125–7.
   Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997; 337: 141–7.
   Google Scholar
• Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and the IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39: 1092–1101.
   Google Scholar
• Bresnihan B, on behalf of the collaborating investigators, Lookabaugh J, Witt K, Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhlL-lra) in rheumatoid arthritis (RA): results of an randomized double-blind, placebo-controlled multicenter trial. Arthritis Rheum. 1996; 39 (suppl.): S73.
   Google Scholar
• Epstein WV. Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Arthritis Rheum. 1996; 39: 1773–80.
   Google Scholar
• McCarthy M. Gene therapy for rheumatoid arthritis starts clinical trials. Lancet. 1996; 348: 323.
   Google Scholar
• Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL. Effects of oral administration of Type II collagen on rheumatoid arthritis. Science. 1993; 26 : 1727–30.
   Google Scholar
• Sleper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA. Oral Type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 1996; 39: 41–51.
   Google Scholar
• Kotzin BL. Systemic lupus erythematosus. Cell. 1996; 85: 303–6.
   Google Scholar
• Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot M-C, Durand-Gasselin I, Morel-Fourrier B, Galanaud P, Emilie D. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw. 1993; 4: 421–30.
   Google Scholar
• Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum. 1996; 39: 379–85.
   Google Scholar
• Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer J-P, Renauld J-C. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995; 4: 393–5.
   Google Scholar
• Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Se- govia D, Ruiz-Soto R, Alcocer-Castillejos N, Alcocer-Varela J, Granados J, Bahena S, Galanaud P, Emilie D. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1429–35.
   Google Scholar
• Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wij denes J, Alcocer-Varela J, Morel-Fourrier B, Brouet J-C, Alarcon-Segovia D, Galanaud P, Emilie D. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995; 181: 839–44.
   Google Scholar
• Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antivodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994; 179: 305–10.
   Google Scholar
• Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T-cells of lupus. J Exp Med. 1993; 177: 1367–81.
   Google Scholar
• Goldman M. Advances in immunotherapy. Editorial introduction: cellular and molecular bases of modern immunotherapy. Acta Clin Belg. 1997; 52: 193–8.
   Google Scholar
• Datta SK, Kalled SL. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. 1997; 40: 1735–45.
   Google Scholar
• Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995; 154: 1470–80.
   Google Scholar
• Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996; 97: 2063–73.
   Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994; 265: 1225–7.
   Google Scholar